Novavax (NVAX) Set to Post Earnings on Thursday

Novavax (NASDAQ:NVAX) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.3459) per share and revenue of $50.42 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.06. The business had revenue of $56.70 million for the quarter, compared to analysts’ expectations of $52.51 million. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The firm’s revenue for the quarter was down 76.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.62 EPS. On average, analysts expect Novavax to post ($0.38) EPS for the current fiscal year and $0.06 EPS for the next fiscal year.

Novavax Stock Performance

NVAX stock opened at $9.53 on Tuesday. The company has a market capitalization of $1.57 billion, a P/E ratio of -6.27 and a beta of 2.44. Novavax has a 52-week low of $6.20 and a 52-week high of $13.39. The business has a 50-day simple moving average of $10.47 and a two-hundred day simple moving average of $9.30.

Analysts Set New Price Targets

NVAX has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Zacks Research downgraded shares of Novavax from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Novavax in a report on Tuesday, October 27th. Citigroup reaffirmed a “sell” rating and issued a $8.00 target price (up from $7.00) on shares of Novavax in a report on Thursday, October 15th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Novavax in a research report on Monday. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $12.33.

Novavax Company Profile

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.